

COSTEM 2022 – Scientific Program

All times in CET

Thursday, October 27	
18:30	Welcome Reception
Friday, October 28	
	Hall A
08:00 – 09:00	Industry session timeslot
09:00 – 09:15	Short Break
09:15 – 10:45	Session 1: Opening Session – CAR vs. HSCT
09:15 – 09:25	Welcome note: <u>Nicolaus Kröger</u> , Germany; <u>Arnon Nagler</u> , Israel
09:25 – 09:55	Does CAR T cell replace stem cell transplantation in DLBCL? Chair: <u>Nicolaus Kröger</u> , Germany
09:25 – 09:40	Yes: <i>TBA</i>
09:40 – 09:55	No: <u>Michael Bishop</u> , USA
09:55 – 10:25	Controversy: Will CAR-T-cell replace stem cell transplantation in MM? Chair: <u>Arnon Nagler</u> , Israel
09:55 – 10:10	Yes: <u>Noopur Raje</u> , USA
10:10 – 10:25	No: <u>Philippe Moreau</u> , France
10:25 – 10:45	Panel discussion: <i>All</i>
10:45 – 11:15	<i>Coffee Break, Poster Viewing and Visit Exhibition</i>
	Hall A
11:15 – 12:45	Session 2: AML
11:15 – 11:45	Controversy: Should MRD positivity targeted prior SCT or after SCT? Chair: <u>Yi-Bin Chen</u> , USA
11:15 – 11:30	Prior: <u>Arnon Nagler</u> , Israel
11:30 – 11:45	After: <u>Michael Heuser</u> , Germany
11:45 – 12:15	Controversy: Narrow vs. broad (specific vs. nonspecific) TKI post Allo in FLT3+ AML Chair: <u>Andreas Burchert</u> , Germany
11:45 – 12:00	Broad: <u>Xiaojun Huang</u> , China
12:00 – 12:15	Narrow: <u>Yi-Bin Chen</u> , USA
12:15 – 12:45	Panel discussion: <i>All</i>
	Hall B
11:15 – 12:45	Session 3: Infection complications
11:15 – 11:45	Controversy: Letermovir prophylaxis as secondary prophylaxis? Chair: <u>Rafael de la Cámara</u> , Spain
11:15 – 11:30	Yes: <u>Michael Boeckh</u> , USA
11:30 – 11:45	No: <u>Per Ljungman</u> , Sweden
11:45 – 12:15	Controversy: Are there evidence-based arguments for a general compulsory SarsCoV2 vaccinations? Chair: <u>Per Ljungman</u> , Sweden
11:45 – 12:00	Yes: <u>Simone Cesaro</u> , Italy
12:00 – 12:15	No: <i>TBA</i>
12:15 – 12:45	Panel discussion: <i>All</i>
12:45 – 13:15	<i>Lunch Pick-up, Poster Viewing and Visit Exhibition</i>
13:15 – 14:15	Industry session timeslot

<b>14:15 – 14:30</b>	<i>Short Break</i>	
	<b>Hall A</b>	<b>Hall B</b>
<b>14:30 – 16:00</b>	<b>Session 4: GVHD prophylaxis /Treatment (1)</b>	<b>Session 5: MDS</b>
<b>14:30 – 15:00</b>	Controversy: Is there still a role for T cell depletion (CD34 purification) as GVHD prophylaxis in HLA matched (MSD and MUD) Allograft? Chair: <u>Leonido Luznik, USA</u> Yes: <i>TBA</i> No: <u>Marcelo Pasquini, USA</u>	Controversy: Are sequential conditioning regimens the standard for MDS EB1 and EB2? Chair: <u>Bart Lee Scott, USA</u> Yes: <u>Thomas Schroeder, Germany</u> No: <u>Avichai Shimoni, Israel</u>
14:30 – 14:45 14:45 – 15:00		
<b>15:00 – 15:30</b>	Controversy: Can we modify schedule or dosing of PTCy? Chair: <u>Marcelo Pasquini, USA</u> Yes: <u>Christopher Kanakry, USA</u> No: <u>Leonido Luznik, USA</u>	Controversy: Is the new Molecular IPSS helpful for decision making regarding allo? Chair: <u>Avichai Shimoni, Israel</u> Yes: <u>Matteo Della Porta, Italy</u> No: <u>Bart Lee Scott, USA</u>
15:00 – 15:15 15:15 – 15:30		
<b>15:30 – 16:00</b>	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
<b>16:00 – 16:30</b>	<i>Coffee Break, Poster Viewing and Visit Exhibition</i>	
<b>16:30 – 17:30</b>	<i>Industry session timeslot</i>	
<b>17:30 – 17:45</b>	<i>Short Break</i>	
	<b>Hall A</b>	<b>Hall B</b>
<b>17:45 – 19:15</b>	<b>Session 6: GVHD prophylaxis/ Treatment (2)</b>	<b>Session 7: ALL</b>
<b>17:45 – 18:15</b>	Controversy: Do novel agents replace ECP as second line treatment in cGVHD? Chair: <u>Steven Pavletic, USA</u> Yes: <u>Daniel Wolff, Germany</u> No: <u>Hildegard Greinix, Austria</u>	Controversy: Is lower than 12 Gy TBI dose justified as conditioning for allo in young adult ALL? Chair: <u>Sebastian Giebel, Poland</u> Yes: <u>Alexandros Spyridonidis, Greece</u> No: <u>David Marks, UK</u>
17:45 – 18:00 18:00 – 18:30		
<b>18:15 – 18:45</b>	Controversy: Is CNI plus antimetabolite still the standard GvHD prophylaxis for MUD in 2022? Chair: <u>Hildegard Greinix, Austria</u> Yes: <u>Robert Zeiser, Germany</u> No: <i>TBA</i>	Controversy: Is there still a place for upfront allo in Ph+ ALL? Chair: <u>David Marks, UK</u> Yes: <u>Matthias Stelljes, Germany</u> No: <u>Robin Foà, Italy</u>
18:15 – 18:30 18:30 – 18:45		
<b>18:45 – 19:15</b>	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>

<b>Saturday, October 29</b>		
	<b>Hall A</b>	<b>Hall B</b>
<b>08:00 – 09:30</b>	<b>Session 8: Acute Leukemia and CARs</b>	<b>Session 9: SAA</b>
<b>08:00 – 08:30</b>	Controversy: Can CAR T cell therapy replace allo SCT in adult ALL? Chair: <u>Arnon Nagler, Israel</u> Yes: <u>Claire Roddie, UK</u> No: <u>Sebastian Giebel, Poland</u>	Controversy: Can allogeneic SCT with 10/10 MUD be used as first line therapy for sAA? Chair: <u>Carlo Dufour, Italy</u> Yes: <u>Andrea Bacigalupo, Italy</u> No: <u>Antonio Risitano, Italy</u>
08:00 – 08:15 08:15 – 08:30		

08:30 – 09:00	Controversy: Is there a role of CAR T cell or therapy in AML in 2022? Chair: <u>Marion Subklewe, Germany</u> 08:30 – 08:45 Yes: <u>Saar Gill, USA</u> 08:45 – 09:00 No: <u>Charles Craddock, UK</u>	Controversy: <i>TBA</i>
09:00 – 09:30	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
09:30 – 10:00	<i>Coffee Break, Poster Viewing and Visit Exhibition</i>	
10:00 – 11:00	<b>Industry session timeslot</b>	
11:00 – 11:15	<i>Short Break</i>	
	<b>Hall A</b>	<b>Hall B</b>
11:15 – 12:45	<b>Session 10: Multiple Myeloma</b>	<b>Session 11: Lymphoma/ Lymphatic malignancies</b>
11:15 – 11:45	Controversy: CAR vs. Bites in R/R MM Chair: <u>Sergio Giralt, USA</u> 11:15 – 11:30 CAR: <i>TBA</i> 11:30 – 11:45 BITES: <u>Hermann Einsele, Germany</u>	Controversy: NHL-patients achieving <PR 6 mo post CAR should we go Allo? Chair: <u>David Porter, USA</u> Yes: <i>TBA</i> No: <i>TBA</i>
11:45 – 12:15	Controversy: Is it still justified to collect CD34 cells for 2 or more transplants in MM? Chair: <u>Hartmut Goldschmidt, Germany</u> 11:45 – 12:00 Yes: <u>Pieter Sonneveld, Netherlands</u> 12:00 – 12:15 No: <u>Sergio Giralt, USA</u>	Controversy: Is there a role for cellular therapies in CAR-T .. CLL? Chair: <i>TBA</i>  Yes: <u>David Porter, USA</u> No: <i>TBA</i>
12:15 – 12:45	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
12:45 – 13:15	<i>Lunch Pick-up, Poster Viewing and Visit Exhibition</i>	
13:15 – 14:15	<b>Industry session timeslot</b>	
14:15 – 14:30	<i>Short Break</i>	
	<b>Hall A</b>	<b>Hall B</b>
14:30 – 16:00	<b>Session 12: Myelofibrosis</b>	<b>Session 13: Pediatric ALL</b>
14:30 – 15:00	Controversy: Does mutation panel dictate Allo indication in myelofibrosis? Chair: <u>Alessandro Rambaldi, Italy</u> 14:30 – 14:45 Yes: <u>Francesco Passamonti, Italy</u> 14:45 – 15:00 No: <u>Nicolaus Kröger, Germany</u>	Controversy: For pediatric ALL relapsing post CD19 CAR should we go to an alternative CAR? Chair: <u>Christina Peters, Austria</u> Yes: <u>Alan Wayne, USA</u> No: <u>Peter Bader, Germany</u>
15:00 – 15:30	Controversy: Is there a role for haplo or cord blood transplantation in in myelofibrosis? Chair: <u>Nicolaus Kröger, Germany</u> 15:00 – 15:15 Yes: <u>Alessandro Rambaldi, Italy</u> 15:15 – 15:30 No: <u>Nico Gagelmann, Germany</u>	Controversy: Can PBSC be used as stem cell source in MUD pediatric ALL? Chair: <u>Alan Wayne, USA</u>  Yes: <u>Christina Peters, Austria</u> No: <u>Michael Pulsipher, USA</u>
15:30 – 16:00	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
16:00 – 16:30	<i>Coffee Break, Poster Viewing and Visit Exhibition</i>	

16:30 – 17:30	<b>Industry session timeslot</b>	
17:30 – 17:45	<i>Short Break</i>	
	Hall A	Hall B
17:45 – 19:15	<b>Session 14: Stem cell donors</b>	<b>Session 15: Hemoglobinopathy</b>
17:45 – 18:15	Controversy: Can expanded CBT compete with Haplo SCT? Chair: <u>Vanderson Rocha, Brazil</u>	Controversy: Is PTCY the preferred GvHD prophylaxis after haplo-ident SCT in sickle cell anemia? Chair: <u>Rupert Handgretinger, Germany</u>
18:15 – 18:30	Yes: <u>Guillermo Sanz, Spain</u>	Yes: <u>Josu de la Fuente, UK</u>
18:30 – 18:45	No: <u>Francesca Bonifazi, Italy</u>	No: <u>Selim Corbacioglu, Germany</u>
18:45 – 19:15	Controversy: Is PBSC as stem cell source equal to BM after Haplo PTCy? Chair: <u>Francesca Bonifazi, Italy</u>	Controversy: Can gene therapy replace allogeneic SCT in thalassemia? Chair: <u>Selim Corbacioglu, Germany</u>
18:45 – 19:00	Yes: <u>Vanderson Rocha, Brazil</u>	Yes: <u>Rupert Handgretinger, Germany</u>
19:00 – 19:15	No: <i>TBA</i>	No: <u>Suradej Hongeng, Thailand</u>
19:15 – 19:45	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
19:45 – 20:30	<b>COSTEM Poster Walk and Awards</b>	

<b>Sunday, October 30</b>	
	Hall A
09:00 – 10:30	<b>Session 16: Cellular therapies</b>
09:00 – 09:30	Controversy: Can allo NK CAR complete with auto CAR T? Chair: <i>TBA</i>
09:00 – 09:15	Yes: <u>Evelyn Ullrich, Germany</u>
09:15 – 09:30	No: <i>TBA</i>
09:30 – 10:00	Controversy: <i>TBA</i>
09:30 – 09:45	
09:45 – 10:00	
10:00 – 10:30	Panel discussion: <i>All</i>
10:30 – 11:00	<i>Coffee Break</i>
11:00 – 12:30	<b>Session 17: Selection of CAR T cells</b>
11:00 – 11:30	Controversy: Should we preference a CD19 CAR construct in RR DLBCL? Chair: <u>Michael Bishop, USA</u>
11:00 – 11:15	Yes: <u>Wolfgang Bethge, Germany</u>
11:15 – 11:30	No: <u>Marion Subklewe, Germany</u>

<b>11:30 – 12:00</b>	Controversy: Should we preference a BMCA CAR construct in R/R myeloma? Chair: <u>Hermann Einsele</u> , Germany
11:30 – 11:45	Yes: <u>Michael Hudecek</u> , Germany
11:45 – 12:00	No: <u>He Huang</u> , China
<b>12:00 – 12:30</b>	Panel discussion: <i>All</i>
<b>12:30</b>	Closing remarks: <u>Nicolaus Kröger</u> , Germany; <u>Arnon Nagler</u> , Israel